Fulgent Genetics acquires Bako Diagnostics and StrataDx

Fulgent Genetics agreed to acquire Bako Diagnostics and StrataDx. Reported deal value: $55.5M. Status: Announced. Sector: laboratory services. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-03-18. Figures and status may change as filings and press coverage update.

Fulgent Genetics , Inc. , a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics , a premier pathology laboratory , and StrataDx , a premier dermatopathology laboratory , as previously announced on December 22, 2025